Overview:

Summary

Global Markets Direct’s, 'Gastroenteritis - Pipeline Review, Q2 2011', provides an overview of the Gastroenteritis therapeutic pipeline. This report provides information on the therapeutic development for Gastroenteritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gastroenteritis. 'Gastroenteritis - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Gastroenteritis.
- A review of the Gastroenteritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Gastroenteritis pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Gastroenteritis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Gastroenteritis pipeline depth and focus of Gastroenteritis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Gastroenteritis Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Gastroenteritis 7
Gastroenteritis Therapeutics under Development by Companies 9
Late Stage Products 10
Comparative Analysis 10
Early Clinical Stage Products 11
Comparative Analysis 11
Pre-Clinical Stage Products 12
Comparative Analysis 12
Gastroenteritis Therapeutics - Products under Development by Companies 13
Companies Involved in Gastroenteritis Therapeutics Development 14
Nanotherapeutics, Inc. 14
Bharat Biotech International Limited 14
LigoCyte Pharmaceuticals, Inc. 15
Gastroenteritis - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Late Stage Drug Profiles 21
ROTAVAC - Drug Profile 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Bivalent Norovirus Vaccine - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Filtrum-STI - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Drug For Norovirus - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Gastroenteritis Therapeutics – Drug Profile Updates 26
Gastroenteritis - Featured News 27
Oct 25, 2010: LigoCyte Presents Positive Results From Norovirus Vaccine Challenge Study At IDSA Annual Meeting 27
May 14, 2010: FDA says Healthcare Providers can resume use of Rotarix (Rotavirus Vaccine, Live, Oral) 28
Mar 26, 2010: Updated GlaxoSmithKline statement on European regulatory guidance relating to manufacture of Rotarix (rotavirus vaccine) 28
Nov 30, 2009: Regulatory Update: GSK files Rotarix for prevention of rotavirus in Japan 28
Apr 03, 2008: FDA approves Rotarix [Rotavirus Vaccine, live, oral], the first vaccine licensed to complete the rotavirus immunization series by four months of age  Vaccine offers early protection with only two doses against the most commonly commonly circulating rotavirus types in the U.S. 29
Feb 20, 2008: GSK receives favorable recommendation by FDA advisory committee for Rotarix [rotavirus vaccine, live, oral]  If approved, Rotarix would be the only vaccine indicated to prevent rotavirus caused by the five most commonly circulating types, offering completion of the vaccination by four months of age, with only two doses 29
Nov 23, 2007: New data published in The Lancet show GSK's Rotarix Offers protection against the most common circulating rotavirus types 30
Sep 19, 2007: New data show that GlaxoSmithKline's Rotarix could be given with other routine infant vaccines in the U.S. 31
Aug 14, 2007: GlaxoSmithKline's application for Rotarix is accepted for review by the FDA; If approved, new candidate vaccine could offer completion of the rotavirus vaccination series by four months of age 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 33
Contact Us 33
Disclaimer 33"

List of Tables
Number of Products Under Development for Gastroenteritis, Q2 2011 7
Products under Development for Gastroenteritis – Comparative Analysis, Q2 2011 8
Number of Products under Development by Companies, Q2 2011 9
Comparative Analysis by Late Stage Development, Q2 2011 10
Comparative Analysis by Early Clinical Stage Development, Q2 2011 11
Comparative Analysis by Pre-Clinical Stage Development, Q2 2011 12
Products under Development by Companies, Q2 2011 13
Nanotherapeutics, Inc., 2011 14
Bharat Biotech International Limited, 2011 14
LigoCyte Pharmaceuticals, Inc., 2011 15
Assessment by Monotherapy Products, Q2 2011 16
Assessment by Stage and Route of Administration, Q2 2011 18
Assessment by Molecule Type, Q2 2011 20
Gastroenteritis Therapeutics – Drug Profile Updates 26"

List of Figures
Number of Products under Development for Gastroenteritis, Q2 2011 7
Products under Development for Gastroenteritis – Comparative Analysis, Q2 2011 8
Products under Development by Companies, Q2 2011 9
Late Stage Products, Q2 2011 10
Early Clinical Stage Products, Q2 2011 11
Pre-Clinical Stage Products, Q2 2011 12
Assessment by Monotherapy Products, Q2 2011 16
Assessment by Route of Administration, Q2 2011 17
Assessment by Stage and Route of Administration, Q2 2011 18
Assessment by Molecule Type, Q2 2011 19
Assessment by Stage and Molecule Type, Q2 2011 20